

Methylation profiling report



Supplier information

Sample identifier:	sampleName1527692501	Automatic prediction	
Sentrix ID:	202273260034_R06C01	Array type:	EPIC
Material type:	FFPE DNA	Material type:	KRYO DNA
Gender:	NA	Gender:	male
Supplier diagnosis:	-	Legend: ✔ OK ⚠ Supplier information or prediction not available ✖ Warning, mismatch of prediction and supplier information	

Brain tumor methylation classifier results (v11b4)

Methylation classes (MCs with score >= 0.3)	Calibrated score	Interpretation
methylation class family Glioblastoma, IDH wildtype	0.95	match ✔
MC family members with score >= 0.1		
methylation class glioblastoma, IDH wildtype, subclass midline	0.9	match ●


Legend: ✔ Match (score >= 0.9) ✖ No match (score < 0.9): possibly still relevant for low tumor content and low DNA quality cases. ● Match to MC family member (score >= 0.5)

Class descriptions

Methylation class family Glioblastoma, IDH wildtype: The methylation class family "Glioblastoma, IDH wildtype" comprises the methylation classes glioblastoma, IDH wildtype, subtype RTK I to III, glioblastoma, IDH wildtype, subtype mesenchymal, glioblastoma, IDH wildtype, subtype MYCN and glioblastoma, IDH wildtype, subtype midline.


Methylation class glioblastoma, IDH wildtype, subclass midline : The methylation class "glioblastoma, IDH wildtype, subclass midline" is comprised of tumors with a histological diagnosis of glioblastoma, located in midline structures (thalamus, cerebellum, spine). Median age is 13 years (range 2 to 79). Tumors of this class share epigenetic similarities with histone 3 K27M-mutated tumors, but lack this mutation. Mutations of FGFR1 are relatively common, particularly in thalamic tumors. Copy number changes are numerous, the most frequent changes being gain/amplification of PDGFR-alpha and loss of CDKN2A/B (both in over 70% of cases).

Copy number variation profile



Depiction of chromosome 1 to 22 (and X/Y if automatic prediction was successful). Gains/amplifications represent positive, losses negative deviations from the baseline. 29 brain tumor relevant gene regions are highlighted for easier assessment.
(see Hovestadt & Zapatka, <http://www.bioconductor.org/packages/devel/bioc/html/conumee.html>)

MGMT promotor methylation (MGMT-STP27)



(see Bady et al, J Mol Diagn 2016; 18(3):350-61)

Disclaimer

Classification using methylation profiling is a research tool under development, it is not verified and has not been clinically validated. Implementation of the results in a clinical setting is in the sole responsibility of the treating physician. Intended for non-commercial use only.

Run information

Report: idat_reportBrain_v11b4_sample Version 2.0
Task version:

Task	Version
idat_qc	2.0
idat_predictBrain	2.1
idat_rs_gender	2.0
idat_predictMGMT	2.0
idat_cnvp	3.0
idat_reportBrain_v11b4	2.0